Researcher in lab

Find clinical trials

Our clinical trial portfolio is one of the largest in the country. We have more than 700 clinical trials open across 30 clinical units.

Find Melbourne Sexual Health Centre research studies and clinical trials
Clear filter
599 clinical trials found
Clinical trials

SPYRAL AFFIRM

The SPYRAL AFFIRM Global Clinical Study of Renal Denervation with the Symplicity Spyral Renal Denervation System in Subjects with Uncontrolled Hypertension (SPYRAL AFFIRM) (NCT05198674)

Currently recruiting

STALL HFpEF 2

Randomized trial of medical therapy versus conduction system pacing with AV node ablation in persistent atrial fibrillation [AF] and heart failure with preserved ejection fraction (ACTRN12625000466448)

Currently recruiting

STAR AF

STRATEGIES FOR CATHETER ABLATION OF PERSISTENT ATRIAL FIBRILLATION: A RANDOMIZED, COMPARATIVE STUDY (STAR AF 3) (NCT04428944)

Currently recruiting

STARWARS

Salvage sTereotactic Ablative radiotherapy for Recurrent prostate cancer With Androgen suppression and Rectal Spacer (ACTRN12625000224426)

Currently recruiting

STOP

The Silicosis Treatment Of Prednisolone (STOP) Study: A pilot study assessing the effectiveness of Prednisolone on respiratory function in adults with silicosis. (ACTRN12623000622606)

Currently recruiting

STOP-GAP

A Randomized Phase III Study of Duration of Anti-PD-1 Therapy in Metastatic Melanoma (STOP-GAP) (NCT02821013)

Currently recruiting

STOP-MS

Phase III, multicentre, randomised, double-blinded, placebo-controlled, MAMS trial of SpironolacTone and famciclOvir in the treatment of Progressive MS to prevent disability progression (STOP-MS) (ACTN12621001502820)

We have selected two potential anti-Epstein-Barr virus therapies (spironolactone and famciclovir) to test in an innovative multi-stage, multi-arm trial in order to identify the best treatment for progressive MS. Treatments will be compared to dummy-treatment.
Coming soon

STOP-MSU

A phase II randomised, placebo-controlled, investigator-driven trial of tranexamic acid within 2 hours of intracerebral haemorrhage (NCT03385928)

Currently recruiting

STOPit

Study of tofacitinib for the treatment of chronic pouchitis (STOPit) (ACTRN12621000173897)

Currently recruiting

STRIKE

STRIKE: Silicosis Treatment with Infliximab – A Key Evaluation (ACTRN12625000499482)

The STRIKE clinical trial at the Alfred Hospital tests whether the medication infliximab can reduce lung inflammation in people with advanced silicosis from artificial stone exposure. This study offers hope for a potential treatment for silicosis, a progressive lung disease that currently has no approved therapy.
Currently recruiting

STRIVE

A Multicenter, Adaptive, Randomized, Controlled Trial Platform to Evaluate Safety and Efficacy of Strategies and Treatments for Hospitalized Patients with Respiratory and Viral Diseases (NCT05605093)

Currently recruiting

SUPER-ED

Solving Unknown Primary cancER Earlier Diagnosis [SUPER-ED]: A stepped wedge cluster randomised controlled trial implementing a Model of Care to support earlier diagnosis (ACTRN12622001504707)

Currently recruiting

SUPERNOVA [Phase 3]

A Phase I/III Randomized, Double-blind Study to Evaluate the Safety and Neutralizing Activity of AZD5156/AZD3152 for Pre-exposure Prophylaxis of COVID-19 in Participants with Conditions Causing Immune Impairment (NCT05648110)

Currently recruiting

SUPERNUS [RENAISSANCE]

A Phase 2, Multicenter, Open Label Safety and Tolerability Study of SPN-817 in Adult Patients with Treatment Resistant Epilepsy (NCT05518578)

Currently recruiting

SuperQoL

Assessing the impact of an intensive dietitian-led telehealth intervention focusing on nutritional adequacy and symptom control, on quality of life in patients with pancreatic cancer: a randomised control trial. (ACTRN12624000084583)

Currently recruiting

SURFACE ONCOLOGY

A Randomized Phase 2 Trial of Atezolizumab and Bevacizumab in Combination With SRF388 or Placebo in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (NCT05359861)

Currently recruiting

SWIFT

Symptom monitoring WIth Feedback Trial (SWIFT) (ACTRN12620001061921)

Currently recruiting

SYNCOPE-STOPPER

The Syncope-Stopper study: comparison of upfront pacing with standard care for high-risk patients with unexplained syncope. (ACTRN12622001553763)

Currently recruiting

TACTI-004

TACTI-004, a double-blinded, randomized phase 3 trial in patients with advanced/metastatic non-small cell lung cancer [NSCLC] receiving eftilagimod alfa [MHC class II agonist] in combination with pembrolizumab [PD-1 antagonist] and chemotherapy.

The purpose of this study is to compare eftilagimod alfa (efti) in combination with pembrolizumab and chemotherapy versus placebo in combination with pembrolizumab and chemotherapy among adults with metastatic non-small cell lung cancer (NSCLC).
Currently recruiting

TAIHO 10058060

A Phase 1 study of TAS-116 (pimitespib) in combination with imatinib in patients with advanced gastrointestinal stromal tumor (NCT05245968)

Currently recruiting
25 26 27 28 29